Moderna (MRNA) Operating Leases (2018 - 2026)

Moderna (MRNA) has 9 years of Operating Leases data on file, last reported at $645.0 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 3.3% year-over-year to $645.0 million in Q1 2026; TTM through Mar 2026 was $645.0 million, a 3.3% decrease from a year earlier, with the FY2025 full-year figure at $653.0 million, down 2.68% from the prior year.
• Operating Leases for Q1 2026 stood at $645.0 million, down from $653.0 million in the prior quarter.
• Over the last five years, Operating Leases for MRNA reached as high as $697.0 million in Q3 2023 and fell as low as $92.0 million in Q4 2022.
• Historically, Operating Leases has averaged $473.1 million across 5 years, with a median of $653.0 million in 2025.
• Across the five-year window, Operating Leases declined 13.21% in 2022 and surged 598.91% in 2023, its largest moves.
• Year by year, Operating Leases stood at $92.0 million in 2022, then surged by 598.91% to $643.0 million in 2023, then climbed by 4.35% to $671.0 million in 2024, then fell by 2.68% to $653.0 million in 2025, then dropped by 1.23% to $645.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $645.0 million in Q1 2026, $653.0 million in Q4 2025, and $677.0 million in Q3 2025.